Asaf Danziger, Chief Executive Officer at NovoCure Ltd (NVCR), sold 235,000 shares at $108.00 ($25.7M) on 2023-01-05, disclosed to the SEC on 2023-01-09.
Seasonal sale ($25.7M) by Chief Executive Officer — this insider has traded NVCR in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $108.00 | 187,500 | $20.3M | 78.9% |
| 2 | $111.23 | 8,369 | $931K | 3.6% |
| 3 | $111.23 | 8,369 | $931K | 3.6% |
| 4 | $112.86 | 2,000 | $226K | 0.9% |
| 5 | $114.35 | 4,568 | $522K | 2.0% |
| 6 | $114.35 | 4,568 |
| $522K |
| 2.0% |
| 7 | $115.21 | 3,702 | $427K | 1.7% |
| 8 | $115.21 | 3,702 | $427K | 1.7% |
| 9 | $116.06 | 1,395 | $162K | 0.6% |
| 10 | $116.06 | 1,395 | $162K | 0.6% |
| 11 | $117.01 | 999 | $117K | 0.5% |
| 12 | $117.01 | 999 | $117K | 0.5% |
| 13 | $118.47 | 2,123 | $252K | 1.0% |
| 14 | $118.47 | 2,123 | $252K | 1.0% |
| 15 | $119.35 | 1,344 | $160K | 0.6% |
| 16 | $119.35 | 1,344 | $160K | 0.6% |
| 17 | $119.99 | 500 | $60K | 0.2% |
| Total | $109.26 avg | 235,000 | $25.7M | 100% |
| Filing → |
| NVCR | SELL | 2020-12-22 | $61.4M | — | Filing → |
| NVCR | SELL | 2020-09-17 | $10.2M | — | Filing → |
| NVCR | SELL | 2019-11-26 | $9.8M | — | Filing → |